{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:39:46Z","timestamp":1787668786355,"version":"build-2736575974"},"reference-count":15,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>\n                    Long-acting delivery modalities of HIV pre-exposure prophylaxis (PrEP), such as subdermal implants, are in development. To facilitate end-user uptake and sustained use, it is critical to understand potential consumers' and physician prescribers' preferences about, interest in, and relative importance of different implant features. The ordered identification of these key attributes allows implant developers to incorporate this feedback into product design, which theoretically improves acceptability, feasibility, and user experience with the device. In this study,\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    \u2009=\u200975 PrEP-prescribing physicians and\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    \u2009=\u2009143 men having sex with men (MSM) at risk for HIV completed web-based surveys that directly compared the importance of eight to nine different implant features, respectively. Conjoint analysis determined the importance of these features, relative to each other. Implants presented in the study were well received, with a majority of physicians and MSM indicating that they were likely to recommend or use them. The implant was perceived as unique, reliable, and convenient, as well as able to deliver better compliance. The attributes most critical to the adoption of the implant among physicians and MSM were (1) the chance of becoming infected with HIV while on implant treatment, (2) the length of protection and size of the implant, and (3) the side effect advantages over current PrEP oral pill treatment. Some concerns about the implant included side effects and the product's safety (among MSM) and the cost or insurance coverage level for the implant (both physicians and MSM). There was also some resistance to the implantation procedure itself.\n                  <\/jats:p>","DOI":"10.1089\/aid.2021.0075","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T10:19:07Z","timestamp":1636798747000},"page":"336-345","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Conjoint Analysis of User Acceptability of Sustained Long-Acting Pre-Exposure Prophylaxis for HIV"],"prefix":"10.1177","volume":"38","author":[{"given":"Robert J.","family":"Schieffer","sequence":"first","affiliation":[{"name":"Northwestern University, Kellogg School of Management, Evanston, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Bryndza Tfaily","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"D'Aquila","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Greene","sequence":"additional","affiliation":[{"name":"Department of Medical Social Sciences, Institute for Sexual Gender Minority Health and Wellbeing, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Carballo-Di\u00e9guez","sequence":"additional","affiliation":[{"name":"HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Giguere","sequence":"additional","affiliation":[{"name":"HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Tagliaferri Rael","sequence":"additional","affiliation":[{"name":"HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick F.","family":"Kiser","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Northwestern University, Evanston, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7183-8319","authenticated-orcid":false,"given":"Thomas J.","family":"Hope","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"FDA. FDA approves first drug for reducing the risk of sexually acquired HIV infection 2012. Available at https:\/\/www.hiv.gov\/blog\/fda-approves-first-drug-for-reducing-the-risk-of-sexually-acquired-hiv-infection accessed December17 2021."},{"key":"e_1_3_4_3_2","unstructured":"FDA. FDA news release: FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic. Available at https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic (2019) accessed December17 2021."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001145"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3463-4"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30089-9"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000219"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000591"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-016-1565-9"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1108\/13522759810197550"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2018.0214"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2019.1587352"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02703-5"},{"key":"e_1_3_4_14_2","unstructured":"Rael CT Bockting WO MacCrate C et al. Barriers and facilitators to potential future long-acting biomedical HIV prevention strategies for transgender women. 9th IAS Conference on HIV Science. Paris France 2017."},{"key":"e_1_3_4_15_2","volume-title":"9th Annual IAS Conference on HIV Science","author":"Greene GJ","unstructured":"Greene GJ, , Matson M, , D'Aquila RT. Acceptability of emerging technologies for sustained, long-acting HIV pre-exposure prophylaxis (PrEP) among young men who have sex with men (MSM) in the U.S. 9th Annual IAS Conference on HIV Science. Paris, France, 2017."},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30304-0"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2021.0075","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2021.0075","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2021.0075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:16:22Z","timestamp":1777367782000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/aid.2021.0075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1089\/aid.2021.0075"],"URL":"https:\/\/doi.org\/10.1089\/aid.2021.0075","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}